April 15, 2026 | 37 minutes | Hot Topics in Kidney Health
Episode Description
Behind every kidney cancer diagnosis is a person navigating difficult decisions about treatment and care. Today, we’re diving into how to navigate the side effects of kidney cancer treatments and how to tell the difference between side effects and warning signs. Supported by Exelixis.
Speaker Notes
Andrew Allers was diagnosed incidentally with clear-cell Renal Cell Carcinoma (RCC) in 2015 after a soccer injury. After a radical nephrectomy and four years of monitoring, Andrew's stage IV diagnosis was made in 2019 with metastases in his rib, hip, lungs and lymph nodes. The bone tumors were radiated, and after two rounds of an immunotherapy combination, a serious auto-immune reaction necessitated a pause in treatment while Andrew's care team figured out a solution. With regular IVIG infusions to manage the adverse reactions, a single-agent immunotherapy was restarted in early 2020 and within a few months a set of scans showed remarkable improvement -- tumors still visible, but "clinically unmeasurable" in the words of his oncologist. Just over a month later, a vision issue took Andrew to the local ER where he was diagnosed with two brain metastases, one of which was in the occipital lobe. The following day an emergency craniotomy was performed, followed by a round of brain radiation. Over the next 18 months, a series of 4 more brain tumors were discovered, radiated and added to the monitoring schedule. Since beginning a TKI in 2022 Andrew has been free of new brain metastases, and the immunotherapy continues to keep the lung and lymph node tumors at bay. After retiring in 2023, Andrew has become active in the Kidney Cancer community, participating in the research grant review process in the CDMRP & KCRP and as a Legislative Advocate for KidneyCAN, an advocacy group that campaigns for federally funded research into Kidney Cancer treatments.
Julia Stevens, PharmD, BCOP is a Clinical Pharmacy Specialist in Ambulatory Oncology at Beth Israel Deaconess Medical Center in Boston, MA. She collaborates with medical oncologists to care for patients with kidney cancer. Her primary clinical responsibilities include educating patients and caregivers, monitoring and supporting those on oral therapies, minimizing the financial toxicity of treatment, and providing drug information and treatment recommendations to her team. Dr. Stevens is also a member of the Kidney Cancer Association Clinical Advisory Board.
Rimda Wanchoo, MD is a Professor of Medicine at the Zucker School of Medicine and full time nephrologist at Northwell Health in NY. She graduated from medical school in India followed by residency at St. Barnabas in New Jersey and fellowship at NY Presbyterian at Weill Cornell. Her interests are taking care of patients with cancer and kidney diseases, glomerular disease and end stage kidney disease. She has been at Northwell for the last 14 years . She also serves as director of quality for the division and medical director of the largest joint venture dialysis unit in the health system. She has published and spoken on several onconephrology topics internationally. She serves as an associate editor for JON and CKJ. She is one of the founding members of American Society of Onconephrology (ASON).
